Get the Stockscreener App
11.57
1.62%
-0.19
After Hours:
11.56
-0.010
-0.09%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Viatris Inc stock is traded at $11.57, with a volume of 3.59M.
It is down -1.62% in the last 24 hours and up +1.58% over the past month.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
See More
Previous Close:
$11.76
Open:
$11.76
24h Volume:
3.59M
Relative Volume:
0.47
Market Cap:
$13.91B
Revenue:
$15.24B
Net Income/Loss:
$-646.50M
P/E Ratio:
7.5621
EPS:
1.53
Net Cash Flow:
$1.88B
1W Performance:
+1.58%
1M Performance:
+1.58%
6M Performance:
+2.84%
1Y Performance:
+24.41%
1-Day Range:
$11.57
$11.81
1-Week Range:
$11.36
$11.93
52-Week Range:
$8.74
$13.62
Viatris Inc Stock (VTRS) Company Profile
Name
Viatris Inc
Sector
Phone
(724) 514-1465
Address
1000 MYLAN BOULEVARD, CANONSBURG
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-23-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-23-23 | Downgrade | Barclays | Equal Weight → Underweight |
| Apr-24-23 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-17-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-27-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-10-22 | Upgrade | UBS | Sell → Neutral |
| Nov-08-22 | Upgrade | Piper Sandler | Underweight → Neutral |
| Oct-21-22 | Resumed | Jefferies | Hold |
| Jun-14-22 | Initiated | UBS | Sell |
| May-10-22 | Downgrade | Piper Sandler | Neutral → Underweight |
| Mar-01-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-01-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-15-21 | Initiated | Citigroup | Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Mar-08-21 | Downgrade | Goldman | Buy → Neutral |
| Mar-02-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-26-21 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-05-21 | Initiated | Argus | Hold |
| Dec-14-20 | Initiated | Bernstein | Mkt Perform |
View All
Viatris Inc Stock (VTRS) Latest News
Lexicon pens licensing deal with Viatris for sotagliflozin - The Pharma Letter
Lexicon sells Viatris rights to cardio drug outside of the U.S. and Europe - BioPharma Dive
Viatris makes good on CEO's dealmaking promise with $25M licensing pact for Lexicon's heart med Inpefa - FiercePharma
Viatris Enters Exclusive Licensing Agreement With Lexicon - Contract Pharma
Lexicon shares hold stock target, buy rating on new Viatris deal - Investing.com
Lexicon partners Viatris for global expansion of sotagliflozin - Yahoo Finance
Viatris to market Lexicon Pharma’s sotagliflozin outside US and Europe - World Pharmaceutical Frontiers
Viatris to market Lexicon's sotagliflozin outside of US, Europe (NASDAQ:VTRS) - Seeking Alpha
Lexicon signs global sotagliflozin license with Viatris - Investing.com
Lexicon Announces Exclusive Licensing Agreement With Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe - The Manila Times
Lexicon signs global sotagliflozin license with Viatris By Investing.com - Investing.com UK
Viatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe - PR Newswire
Viatris 2023 Sustainability Report: Addressing Critical Health and Social Needs in India - CSRwire.com
Viatris Settles Lawsuit, Avoids Antitrust Charges, and Advances Effexor Study - GuruFocus.com
Viatris Inc (VTRS) Shares Up 4.08% on Oct 15 - GuruFocus.com
Ophthalmic Disease Therapeutics Market Analysis by Age-related Macular Degeneration, Diabetic Macular Edema, & Other Retinal Disorders - GlobeNewswire Inc.
Microbial Therapeutic Product Market Size [2024-2034] -Viatris, Roche, Novartis, Amgen Inc., Merck & Co. Inc., Biocon, P – IndiaPolitics.com - IndiaPolitics.com
Viatris Inc. (VTRS): David Einhorn’s Top Stock Pick - Insider Monkey
Viatris Middle East collaborate with ‘mentl’ - ZAWYA
Viatris Inc. (VTRS): A Strategic Shift in Healthcare Investments - Yahoo Finance
Viatris to Report Financial Results for the Third Quarter 2022 and Provide an Update on its February 28 Investor Event on November 7, 2022 - BioSpace
Global Antiemetics Drugs Market to Exhibit Growth at a CAGR of ~6% by 2030 | DelveInsight - GlobeNewswire Inc.
Viatris 2023 Sustainability Report: Reducing Packaging Material - StockTitan
Viatris reports positive results for EFFEXOR in Japan GAD study By Investing.com - Investing.com South Africa
Viatris Inc (VTRS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Innovations By GuruFocus - Investing.com Canada
Pfizer lawsuit claims company didn’t warn Depo-Provera patients about brain tumor risk - Top Class Actions
Viatris reports positive results for EFFEXOR in Japan GAD study - Investing.com
Viatris Announces Positive Top-line Results from Phase 3 Study of EFFEXOR® in Japanese Adults with Generalized Anxiety Disorder (GAD) - StockTitan
Viatris Named to Forbes' Annual List of the World's Best Employers for the Fourth Year in a Row - citybiz
Viatris 2023 Sustainability Report: Expanding Contractor Training - CSRwire.com
Is Viatris Inc. (NASDAQ:VTRS) The Best NASDAQ Stock Under $20? - Insider Monkey
Novo, Viatris Settle Ozempic Patent Row - BioSpace
Novo Nordisk settles US patent fight with Viatris over Ozempic - Reuters
Insomnia Drug Market to Witness Huge Growth by 2024 | Sanofi, Lundbeck, Viatris - openPR
(VTRS) On The My Stocks Page - Stock Traders Daily
Naloxone Market Set to Witness Significant Growth by 2024-2031:Akorn,Inc, Kaleo,Inc., Pfizer Inc, Viatris - EIN News
Amazon.com Inc. stock outperforms competitors despite losses on the day - MSN
Is Viatris Inc. (VTRS) the Best Stock Under $15 To Buy Now? - Insider Monkey
Viatris's SWOT analysis: generic drug maker's stock faces challenges amid growth - Investing.com India
Viatris launches (Pr)Viagra® ODF in Canada: a new oral dissolving film form of the erectile dysfunction treatment - Yahoo Finance
Viatris to close Cork plant with 200 jobs impacted - MSN
Access at scale for sustainable healthcare development - Vietnam Investment Review
Piper Sandler maintains Neutral rating on Viatris stock with steady price target - Investing.com
Viatris delivering high-quality, accessible, and sustainable healthcare solutions - Vietnam Investment Review
Sustainable dynamics for improved patient access - Vietnam Investment Review
XTX Topco Ltd Boosts Stake in Virtus Investment Partners, Inc. (NASDAQ:VRTS) - Defense World
Ventyx gets $27 million investment from Sanofi - The Pharma Letter
Viatris Inc [VTRS] Stock trading around $11.39 per share: What’s Next? - The DBT News
Viatris Inc Stock (VTRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):